Cholesterol drug shows benefit in animal study of Alzheimer's disease

April 3, 2012

A cholesterol drug commonly prescribed to reduce cardiovascular disease risk restores blood vessel function in a mouse model of Alzheimer's disease, according to a study in the April 4 issue of The Journal of Neuroscience. The drug simvastatin (Zocor) — which works by slowing cholesterol production — also improves learning and memory in adult, but not aged Alzheimer's model mice. The findings add to a growing body of evidence that early treatment with statins protects against some of the symptoms of Alzheimer's disease.

Alzheimer's disease destroys nerve cells and compromises the function of in the brain. Recent studies show people who begin taking statins as adults have reduced incidence of Alzheimer's disease, while those who do not take them until they are older do not experience this benefit. While these studies point to the age-dependent benefits of statins, scientists continue to question how treatment affects brain function in Alzheimer's disease.

In a previous study, Edith Hamel, PhD, and colleagues at McGill University tested older Alzheimer's model mice (age twelve months) that received a low dose of for eight weeks. The drug helped improve blood vessel function, but did not boost memory in the older mice.

In the new study, Hamel's group tested younger mice (age six months) and older mice (age twelve months) that received a higher dose of simvastatin for three to six months. While simvastatin restored brain blood vessel function in both groups, only the younger mice showed improvements in learning and memory tests. These younger mice also had higher levels of two memory-related proteins in the hippocampus — a brain region involved in learning and memory — compared with untreated mice.

"This study shows that simvastatin can protect against some of the damaging effects of Alzheimer's disease on nerve cells involved in memory, if administered early in the disease process," said Hamel, the study's senior author.

In people with Alzheimer's disease, protein fragments called amyloid-β (Aβ) form plaques between nerve cells that disrupt cell communication. Normally, these protein fragments are broken down and removed. In Alzheimer's disease, the protein fragments clump together — a factor believed to contribute to memory loss. Hamel's team measured the presence of Aβ proteins in younger and older Alzheimer's model mice that received simvastatin. Despite the learning and memory improvements in younger mice, the drug did not reduce Aβ protein levels in either group.

"This article joins an increasing number of preclinical studies demonstrating that statins, in particular simvastatin — which easily penetrates the brain — can counteract some aspects of Alzheimer's disease, despite seeing no effects on amyloid-β protein," said Ling Li, PhD, an Alzheimer's expert from the University of Minnesota. "Although several clinical trials have yet to show the benefits of statins for Alzheimer's disease, the key now is to figure out how to translate these exciting findings from bench to bedside," she added.

Explore further: Characterizing a toxic offender

Related Stories

Characterizing a toxic offender

December 9, 2011
The brains of individuals with Alzheimer's disease contain protein aggregates called plaques and tangles, which interfere with normal communication between nerve cells and cause progressive learning and memory deficits. Now, ...

Cancer drug improves memory in mouse model of Alzheimer's disease

March 13, 2012
A compound that previously progressed to Phase II clinical trials for cancer treatment slows neurological damage and improves brain function in an animal model of Alzheimer's disease, according to a study in the March 14 ...

Advances in research into Alzheimer's disease

July 9, 2011
Advances in research into Alzheimer's disease: transporter proteins at the blood CSF barrier and vitamin D may help prevent amyloid β build up in the brain

Potential new drug candidate found for Alzheimer's disease

May 31, 2011
Researchers at the University of California, San Diego, the Medical University of South Carolina and American Life Science Pharmaceuticals of San Diego have demonstrated that oral administration of a cysteine protease inhibitor, ...

Alzheimer's protein kills nerve cells in nose

September 27, 2011
A protein linked to Alzheimer's disease kills nerve cells that detect odors, according to an animal study in the September 28 issue of The Journal of Neuroscience. The findings shed light on why people with Alzheimer's disease ...

Recommended for you

PET scans for Alzheimer's could bring benefit to more patients

October 19, 2017
An imaging tool honed to spot rogue proteins in the brain could benefit some patients with suspected Alzheimer's, according to a new study.

One step closer toward a treatment for Alzheimer's disease?

October 18, 2017
Scientists at the Massachusetts General Hospital (MGH), in collaboration with colleagues at the University California, San Diego (UCSD), have characterized a new class of drugs as potential therapeutics for Alzheimer's disease ...

New mechanism detected in Alzheimer's disease

October 13, 2017
McGill University researchers have discovered a cellular mechanism that may contribute to the breakdown of communication between neurons in Alzheimer's disease.

Neuroscientists identify genetic changes in microglia in a mouse model of neurodegeneration and Alzheimer's disease

October 13, 2017
Microglia, immune cells that act as the central nervous system's damage sensors, have recently been implicated in Alzheimer's disease.

Green tea extract delivers molecular punch to disrupt formation of neurotoxic species

October 11, 2017
Green tea is widely considered to be beneficial for the brain. The antioxidant and detoxifying properties of green tea extracts help fight catastrophic diseases such as Alzheimer's. However, scientists have never fully understood ...

Menopause triggers metabolic changes in brain that may promote Alzheimer's

October 10, 2017
Menopause causes metabolic changes in the brain that may increase the risk of Alzheimer's disease, a team from Weill Cornell Medicine and the University of Arizona Health Sciences has shown in new research.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.